FDA Oncology Announcements

VEGFR inhibitor × Genitourinary × Clear all

12 Announcements

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma

Drug: Fotivda (tivozanib) · VEGFR inhibitor
Condition: Genitourinary

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma

Trial: CheckMate 9ER
Drugs: Opdivo (nivolumab) · Anti-PD-1 antibody, Cabometyx (cabozantinib) · VEGFR inhibitor
Condition: Genitourinary

FDA approves avelumab plus axitinib for renal cell carcinoma

Trial: JAVELIN Renal 101
Drugs: BAVENCIO (avelumab) · Anti-PD-L1 antibody, axitinib · VEGFR inhibitor
Condition: Genitourinary

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma

Trial: KEYNOTE-426
Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, axitinib · VEGFR inhibitor
Condition: Genitourinary

FDA grants regular approval to Cabometyx for first-line treatment of advanced renal cell carcinoma

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Condition: Genitourinary

FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma

Trial: S-TRAC
Drug: Sutent (sunitinib malate) · VEGFR inhibitor
Condition: Genitourinary

Cabozantinib (CABOMETYX)

Drug: CABOMETYX (cabozantinib) · VEGFR inhibitor
Condition: Genitourinary

Sorafenib (NEXAVAR)

Drug: NEXAVAR tablets (sorafenib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinalGenitourinary

Axitinib

Drug: Inlyta (axitinib) · VEGFR inhibitor
Condition: Genitourinary

Pazopanib

Drug: VOTRIENT (pazopanib) · VEGFR inhibitor
Condition: Genitourinary

Sorafenib

Drug: Nexavar (sorafenib) · VEGFR inhibitor
Conditions: GastrointestinalGenitourinary

Sunitinib malate

Drug: SUTENT (sunitinib malate) · VEGFR inhibitor
Condition: Genitourinary